ロード中...
Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy
CONTEXT: Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available. OBJECTIVES: To evaluate the effects of 8 years of rhPT...
保存先:
| 出版年: | J Clin Endocrinol Metab |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Endocrine Society
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6530656/ https://ncbi.nlm.nih.gov/pubmed/30776291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02430 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|